You are here

Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

Last updated on May 21, 2019

FOR MORE INFORMATION
Study Location
Arles, , 13200 France
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Enthesitis Spondylarthropathies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Spondylarthropathy

- Heel enthesitis refractory to standard treatment

- Between 18 and 70 years of age

- The patient global assessment of the disease activity (measured by a 100 mm VAS) must
be >40 in the last 48 hours

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Use of > 1 local steroid injection within 2 weeks of screening

- Prior exposure to any TNF-inhibitor, including etanercept

- Dose of NSAIDs changed within two weeks of study drug evaluation

NCT00420303
Pfizer
Completed
Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now